Eligibility. Applicants must meet the following criteria to qualify for a YIA: Be a physician (MD, DO, or international equivalent) working in any country and currently in the last two years of their ...

American Society of Clinical Oncology (ASCO) and Egyptian Cancer Society (ECS) leaders signed a Memorandum of Understanding (MOU) on June 2, 2025, during ASCO’s 61st Annual Meeting. The MOU formally ...

If you are looking for non-scientific summaries for patients, please visit the Patient Information page.. TAPUR Study Analysis Plan. The TAPUR Study is a phase II, non-randomized, open-label clinical ...

Key Dates. Save the Date! The next ASCO Breakthrough will take place June 25-27, 2026, in Singapore and online. Attend the Meeting in Person. ASCO's Media Headquarters is where you can apply for media ...

Meeting. 2023 ASCO Breakthrough. Session Type. Rapid Oral Abstract Session. Session Title. Rapid Abstract Session B: Precision Medicine and Multiomics. Track ...

[177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:. On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, ...

The 2026 cycle opens July 1, 2025. All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent ...

ALEXANDRIA, Va.. — Results from a multinational study found that using artificial intelligence (AI) assistance can help pathologists more accurately classify breast cancers with low levels of HER2 ...

CHICAGO — New study results show that a structured exercise program following surgery and adjuvant chemotherapy reduced the risk of recurrent or new cancer and increased survival for patients with ...

Key Details. For Immediate Release. May 21, 2025 . Contact. Kelly Baldwin. 571-483-1365. [email protected] ...

ALEXANDRIA, Va. — A large observational study of more than 170,000 patients with diabetes and obesity in the United States has found that GLP-1 receptor agonists may modestly reduce the risk of ...